Delving into the Latest Updates on Ivermectin with Synapse

Overview

Basic Info

SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity.

Drug Type

Small molecule drug

Synonyms

mdc-STM

+ [13]

Target

GluCls

Action

modulators

Mechanism

Glutamate-gated chloride channel modulators

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

RosaceaLice InfestationsScabies+ [9]

Inactive Indication

Acne VulgarisDermatitis, AtopicPediculus capitis infestation

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Zhejiang Hisun Pharmaceutical Co., Ltd.

Merck Sharp & Dohme Corp.

MedinCell SA

+ [7]

Inactive Organization

Galderma Holding SAGalderma Research & Development SNCTaro Pharmaceuticals U.S.A., Inc.

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1996),

OnchocerciasisStrongyloidiasis

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS Registry70209-81-3

This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children's Research Institute, Burnet institute and Lao Tropical and Public Health Institute.
ITCHY Study:
The primary objective is to determine in young children aged 2 to <5 years and weighing 10 to <15 kg if an ivermectin dose of 3 mg achieves comparable drug exposures to the recommended dose in older children. It aims to provide reliable evidence for a safe and effective dose of ivermectin in young children who are especially vulnerable to scabies infections and the associated secondary complications.
ITCHY2 Study:
An embedded phase 2 multicentre, open label prospective pharmacokinetic study in Laos PDR of ITCHY Study. The primary objective is to determine the plasma ivermectin drug exposure in children aged 3 months to 2 years and weighing ≥2 kg receiving an age specific ivermectin dose.

Start Date01 Apr 2025

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

NCT06404333

/ RecruitingPhase 2IIT

A Randomized Trial to Assess the Safety, Pharmacokinetics, Acceptability, and Efficacy of Pediatric Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms

The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy

Start Date25 Feb 2025

Sponsor / Collaborator

University of Oxford

[+2]

100 Clinical Results associated with Ivermectin

Login to view more data

100 Translational Medicine associated with Ivermectin

Login to view more data

100 Patents (Medical) associated with Ivermectin

Login to view more data

8,208

Literatures (Medical) associated with Ivermectin

31 Dec 2025·Journal of Dermatological Treatment

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Article

Author: Augustin, M. ; Wagner, J. N. ; Zirkenbach, F. ; Grote, C.

PURPOSEDupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.MATERIAL AND METHODSThis case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.RESULTSFollowing a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.CONCLUSIONSThis case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.

01 Jun 2025·One Health

Treatment of cattle with ivermectin and its effect on dung degradation and larval abundance in a tropical savanna setting

Article

Author: Ruhinda, Miriam ; Brewster, Carlyle ; Meza, Felician ; Lyimo, Issa N ; Xia, Kang ; Shija, Gerald ; Chaccour, Carlos ; Rabinovich, N Regina ; Rist, Cassidy ; Schürch, Roger

When ingested as part of a blood meal, the antiparasitic drug ivermectin kills mosquitoes, making it a candidate for mass drug administration (MDA) in humans and livestock to reduce malaria transmission. When administered to livestock, most ivermectin is excreted unmetabolized in the dung within 5 days post administration. Presence of ivermectin, has been shown to adversely affect dung colonizers and dung degradation in temperate settings; however, those findings may not apply to, tropical environment, where ivermectin MDA against malaria would occur. Here we report results of a randomized field experiment conducted with dung from ivermectin-treated and control cattle to determine the effect of ivermectin on dung degradation in tropical Tanzania. For intact pats, we measured termite colonization, larval numbers and pat wet and dry weights. Pat organic matter was interpolated from a subsample of the pat (10 g wet weight). Additionally, we counted larvae growing in the treated and untreated pats in a semi-field setting. We found that termites colonized ivermectin pats more readily than controls. Despite this, wet weight decreased significantly slower in the ivermectin-treated pats in the first two weeks. As water was lost, sub-sample dry weight increased, and organic matter decreased similarly over time for the treatment and control. Interpolated for whole pats, total organic matter was higher, and larval counts were lower in the ivermectin-treated pats after the first month. Our results demonstrate an effect of ivermectin and its metabolites on dung degradation and fauna in a tropical savanna setting. Because slow dung degradation and low insect abundance negatively impact pastureland, these non-target, environmental effects must be further investigated within the context of real-world implementation of ivermectin MDA in cattle and weighed against the potential benefits for malaria control.

01 Apr 2025·Molecular Diversity

Comprehensive approach to in silico identification and in vitro validation of anti-filarial hit molecules targeting the dimer interface of thioredoxin peroxidase 1 in Wuchereria bancrofti: a progress in anti-filariasis drug development

Article

Author: Sureshan, Muthusamy ; Rajamanikandan, Sundarraj ; Saraboji, Kadhirvel

Lymphatic filariasis (LF) remains a significant health challenge for populations in developing countries. LF is a parasitic disease transmitted by mosquitoes, mainly caused by the filarial nematode, Wuchereria bancrofti, prevalent in tropical and subtropical regions. Since the present drugs develop complications, including adverse side effects, lack of specificity, and development of drug resistance, the present study focused on developing the potential anti-filariasis drugs targeting crucial proteins for the nematode life cycle. We have identified the therapeutic compounds by targeting the enzyme thioredoxin peroxidase 1 (WbTPx1), which facilitates the conversion of hydrogen peroxide into water, an essential mechanism by which the nematode survives against oxidative stress in the host. This approach might resolve treatment efficacy and activity difficulties at various stages of filarial parasitic worms. We modeled the structure of WbTPx1 and employed the structure-based virtual screening approach, focusing on the dimer interface region of the protein. ADMET prediction profiles of the non-toxic, top-ranked hits with higher docking scores demonstrate higher affinity to the nematode protein than its human homolog. The molecular dynamic simulation studies show WbTPx1-hit complexes' stability and the intactness of hits in the binding site. Further, in vitro validation of identified hits using Setaria digitata, a cattle nematode, showed better IC₅₀ and higher inhibition than the standard drug ivermectin, indicating the potential to inhibit enzyme activity and the development of drug candidates for controlling LF.

78

News (Medical) associated with Ivermectin

18 Feb 2025

·www.prnewswire.com

Independent Medical Alliance Publishes Inaugural Issue of the Journal of Independent Medicine

Journal Represents a New Era of Unbiased Medical Research WASHINGTON, Feb. 18, 2025 /PRNewswire/ -- Today, the Independent Medical Alliance (IMA), formerly FLCCC, proudly announces the Journal of Independent Medicine, a groundbreaking peer-reviewed publication dedicated to restoring integrity, transparency, and scientific independence in medical research and education. Continue Reading Journal of Independent Medicine Cover The Journal of Independent Medicine is designed to challenge industry influence, prioritize ethical scientific inquiry, and provide a critical platform for research that mainstream medical journals often ignore or suppress. This includes studies on repurposed medicines, alternative and integrative therapies, medical ethics, constitutional rights in healthcare, and the ongoing implications of COVID-19 and other healthcare policies. A Platform for Honest, Transparent Science Medical research today is increasingly driven by pharmaceutical industry funding, which introduces significant bias in clinical studies and publication decisions. The Journal of Independent Medicine seeks to counteract this trend by: Eliminating Big Pharma Influence – The journal does not accept funding from pharmaceutical companies, ensuring that research is evaluated on scientific merit alone. Encouraging Full Transparency – All authors must disclose conflicts of interest, and submitted research will undergo rigorous, ethical peer review. In addition, for original investigations, the full original data must be available to the reviewers and editors. Championing Underreported Topics – The journal provides a home for controversial and underfunded research, including studies on repurposed medicines, Traditional Chinese Medicine, and non-pharmaceutical interventions. Publishing Negative and Inconclusive Findings – Unlike mainstream journals, which often reject studies that do not show a drug's effectiveness, the Journal of Independent Medicine acknowledges the scientific value of negative results. "Our goal is simple but profound—restore trust in medical research by publishing truthful, high-quality science that is free from corporate and political influence," said Dr. Joseph Varon, Editor-in-Chief of the Journal of Independent Medicine. "This journal will be a sanctuary for researchers and clinicians who want to engage in Honest Medicine and publish findings that can truly help patients, rather than serve financial interests." Dr. Varon further emphasized the journal's global reach and expertise, stating, "With 43 esteemed editorial board members representing 17 different countries, the Journal of Independent Medicine is built on a foundation of diverse perspectives and international collaboration. Each paper undergoes a rigorous double-blind peer review process by our editorial board members, ensuring that research is evaluated solely on its scientific merit, free from bias or external influence." First Issue: February 18, 2025 The inaugural issue of the Journal of Independent Medicine will be offered at no cost on the journal's website () and feature research articles, reviews, and critical discussions on topics including: The hidden mental health crisis among doctors Honest Medicine™ – Reclaiming scientific integrity in medical research COVID-19 patient outcomes retrospective study Traditional Chinese Medicine (Part 1 in a series) Ivermectin and its evolving role in therapeutic medicine Repurposed Medicine – Exploring cost-effective, evidence-based drug repurposing Constitutional Rights in the COVID-19 Era Disparities in access to healthcare Translational fidelity in mRNA vaccines About the Journal of Independent Medicine The Journal of Independent Medicine, published by the Independent Medical Alliance™ (IMA), is a quarterly peer-reviewed, multi-specialty journal dedicated to advancing unbiased medical research. The IMA is a nonprofit, 501(c)(3) organization and coalition of physicians, scientists, and other healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through the empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA drives a movement to create a more compassionate and effective healthcare system. For more information about the Journal of Independent Medicine, visit . For more information about the Independent Medical Alliance, visit Media Contact Lynne Kristensen [email protected] SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

16 Jan 2025

·www.prnewswire.com

Frontline COVID Docs (FLCCC) Gear Up for Kennedy Confirmation Battle; Announce New Name & Expanded Focus

"For many of us, COVID was an eye-opener. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." – Dr. Joseph Varon WASHINGTON, Jan. 16, 2025 /PRNewswire/ -- The Frontline COVID-19 Critical Care Alliance (FLCCC) announced today that the group is changing its name to the Independent Medical Alliance (IMA) as the nation prepares for the coming Kennedy nomination debates. "We're about to have an unprecedented national discussion about America's broken healthcare system," said Dr. Joseph Varon, President and Chief Medical Officer of the Independent Medical Alliance. "For many of us, COVID was an eye-opener. I was on the front lines fighting to save lives. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." Representing over 15,000 doctors and other medical professionals, the FLCCC vaulted to national prominence by pushing back against vaccine mandates and other government induced COVID policy failures, while also advocating for early and cost-effective alternative treatments, including ivermectin, which has proven to be highly effective against COVID. "They demonized accomplished virologists and others who knew that ivermectin was saving lives," continued Varon. "Hundreds of thousands died due to the censorship of debate. At our hospital, we considered alternatives, and our published mortality rate was 4.4% while major hospitals at the time were experiencing 23% to 26% rates of ICU death." "Our success raised interest among those at FDA and CDC, but not the way one would expect. They sent scores of briefcase wielding bureaucrats to try and shut down our treatment programs. We were outside of the PhRMA profit orthodoxy. We were non-conformists. And although we were saving more lives, that didn't appear to be the priority." "The Kennedy confirmations will be about restoring health to America's healthcare systems, and we're looking forward to that discussion," concluded Varon. About the IMA (Formerly FLCCC Alliance) The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system. For more information about the Independent Medical Alliance, visit Contact Lynne Kristensen Independent Medical Alliance [email protected] (202) 987-5655 SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AHA

26 Nov 2024

·www.businesswire.com

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India--( BUSINESS WIRE )--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's. “We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product,” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. Ivermectin Tablets, 3 mg brand and generic products, had U.S. sales of approximately $20 million MAT for the twelve months ending in September 2024 according to IQVIA. RDY-1124-747 About Dr. Reddy’s : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com . About Senores Pharmaceuticals, Inc. : Senores Pharmaceuticals, Inc., based in Georgia, USA, is a wholly owned subsidiary of Senores Pharmaceuticals Limited and one of the fastest-growing pharmaceutical companies in the USA. The company has more than 25 products commercially launched or filed with the USFDA. For more information about Senores Pharmaceuticals, Inc., please visit www.senorespharma.com . Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.

Drug Approval

100 Deals associated with Ivermectin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00804	Ivermectin	D11AX22 P02CF01	DB00602

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rosacea	United States	Galderma Laboratories LP	19 Dec 2014
Lice Infestations	United States	Arbor Pharmaceuticals LLC	07 Feb 2012
Scabies	Japan	MSD KK	21 Aug 2006
Ascariasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Elephantiasis, Filarial	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Enterobiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Helminthiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Hookworm Infections	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Trichuriasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Onchocerciasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996
Strongyloidiasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rosacea	NDA/BLA	European Union	Adalvo Ltd.	18 Apr 2023
COVID-19	Preclinical	Bulgaria	MedinCell SA	25 Mar 2022
Dermatitis, Atopic	Preclinical	Canada	Galderma Research & Development SNC	01 Nov 2016
Dermatitis, Atopic	Preclinical	Canada	Galderma Holding SA	01 Nov 2016
Acne Vulgaris	Preclinical	Canada	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Preclinical	Germany	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Preclinical	Germany	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Preclinical	France	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Preclinical	France	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Preclinical	Canada	Galderma Research & Development SNC	25 Apr 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05305560 (SAIVE, CTgov)	Phase 2	COVID-19	400	Ivermectin Tablets (Active IMP)	edgnzfnphk(txbqqdhkgy) = htbjxbdiox zfwifnmzxx (ktngbcelhs, omukdphadt - waxsfulnyc) View more	-	10 Dec 2024
				Matching placebo tablets (Placebo)	edgnzfnphk(txbqqdhkgy) = wamcezwuxz zfwifnmzxx (ktngbcelhs, xuvipnxfhy - kmrtrvfvpu) View more
NCT04056325 (StrongMoxi, CTgov)	Phase 2/3	Strongyloidiasis	617	Moxidectin (Phase 2a - Arm A (Moxidectin 2 mg))	bljjikwdri(xnqqugpbgo) = wgamgduiqj qvdxzkbflf (jaodriqquw, yqjomjdjxi - vnazgwjwdd) View more	-	09 Dec 2024
				Moxidectin (Phase 2a - Arm B (Moxidectin 4 mg))	bljjikwdri(xnqqugpbgo) = zqlhkyvlue qvdxzkbflf (jaodriqquw, lcsjyvdkdv - cldswxacvf) View more
NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	fsxndvkgmj(zalwzfnufi) = elmoboarcz qmcczqpqcy (huxynnbags, rzzcbqqgso - pmhsfqmyza) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	fsxndvkgmj(zalwzfnufi) = zcdtaolrwd qmcczqpqcy (huxynnbags, ufowltnqkc - bndbeihdmq) View more
NCT04848688 (StrongMoxi_KH, CTgov)	Phase 3	Strongyloidiasis	332	Placebo+Moxidectin 2 mg (Moxidectin)	aammnejacl(qdiumvrwwe) = mzsooqnxdu gkiixvvbdz (yitprgggbz, amaiiphnno - bupzrcrqgb) View more	-	24 Jan 2024
				Placebo+Ivermectin 3 mg (Ivermectin)	aammnejacl(qdiumvrwwe) = ewjrlldewt gkiixvvbdz (yitprgggbz, ztnbnviosw - rvqeceoqlh) View more
NCT03967054 (RIMDAMAL II, CTgov)	Phase 3	Malaria	4,124	Ivermectin (Ivermectin Mass Drug Administration)	vhiatyyvsf(vbaxvsjaav) = rvnqmwipqw sdhtoetpxl (czakdeadhs, wxgbzceqbi - iabcycefxi) View more	-	11 Jan 2024
				Placebo oral tablet (Placebo Mass Administration)	vhiatyyvsf(vbaxvsjaav) = jmjfysckze sdhtoetpxl (czakdeadhs, rznetmlrrn - behabdweib) View more
NCT05894538 (CTgov)	Phase 3	COVID-19	1,459	Ivermectin (Arm D - Ivermectin 600)	ntkunetkik(muvpgpeucb) = uxilfwsajb gbdobzcqjl (khpgvvquhc, bovnwcapbb - ufvouojawo) View more	-	28 Sep 2023
				Placebo (Arm D - Placebo)	ntkunetkik(muvpgpeucb) = elpnnjzbwx gbdobzcqjl (khpgvvquhc, ygnfslijnk - tyazvhizye) View more
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	Elephantiasis, Filarial Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	exqruzcnsg(sdqzjihiri) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) ppksdqszmk (eicosistwj ) View more	Positive	18 Sep 2023
				moxidectin + albendazole
NCT04510194 (COVID-OUT, CTgov)	Phase 3	COVID-19	1,323	Metformin (Treatment Arm - Metformin Only Group)	tnfpmiuwmz(xznbegypxx) = xlvsxyrvip lvrqkgpwpw (ydpetwhtyz, fydzjxhtbx - hhofhnqlho) View more	-	13 Jul 2023
				Placebo (Treatment Arm - Placebo Group)	tnfpmiuwmz(xznbegypxx) = rocjxchejp lvrqkgpwpw (ydpetwhtyz, yiscpgrpib - hlvjsjokzs) View more
WCD2023	Not Applicable	Scabies	-	ivermectin (Community residents)	qcynhvlsbc(uzmjrkgfrb) = fobvehaxdk ckejwccyjx (wbvfdcxmpy )	-	06 Jul 2023
WCD2023	Not Applicable	Rosacea	-	Ivermectin 1% cream and doxycycline 40 mg	vfwkmuowcx(fiebgncwqc) = jommxrfzaw kdjfxnmsei (pmbcdqcmwo )	-	03 Jul 2023
				Ivermectin 1% cream and Placebo	vfwkmuowcx(fiebgncwqc) = rlirmgaqrl kdjfxnmsei (pmbcdqcmwo )